WO2005056056A3 - The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist - Google Patents

The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist Download PDF

Info

Publication number
WO2005056056A3
WO2005056056A3 PCT/DK2004/000862 DK2004000862W WO2005056056A3 WO 2005056056 A3 WO2005056056 A3 WO 2005056056A3 DK 2004000862 W DK2004000862 W DK 2004000862W WO 2005056056 A3 WO2005056056 A3 WO 2005056056A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorder
disorders
serotonin reuptake
reuptake inhibitor
agonist
Prior art date
Application number
PCT/DK2004/000862
Other languages
French (fr)
Other versions
WO2005056056A2 (en
Inventor
Thomas Ivo Franciscus Cremers
Willigers Sandra Hogg
Original Assignee
Lundbeck & Co As H
Thomas Ivo Franciscus Cremers
Willigers Sandra Hogg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0415899-7A priority Critical patent/BRPI0415899A/en
Priority to JP2006543369A priority patent/JP2007513896A/en
Priority to US10/596,348 priority patent/US20070066601A1/en
Priority to CA002549574A priority patent/CA2549574A1/en
Priority to EA200601158A priority patent/EA200601158A1/en
Priority to EP04803015A priority patent/EP1696896A2/en
Application filed by Lundbeck & Co As H, Thomas Ivo Franciscus Cremers, Willigers Sandra Hogg filed Critical Lundbeck & Co As H
Priority to AU2004296531A priority patent/AU2004296531A1/en
Publication of WO2005056056A2 publication Critical patent/WO2005056056A2/en
Publication of WO2005056056A3 publication Critical patent/WO2005056056A3/en
Priority to IS8388A priority patent/IS8388A/en
Priority to IL176238A priority patent/IL176238A0/en
Priority to NO20063267A priority patent/NO20063267L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention relates to the use of a compound, which is a serotonin reuptake inhibitor, and another compound, which is a H3 receptor antagonist, inverse agonist or partial agonist for the preparation of a pharmaceutical composition for the treatment of depression, anxiety disorders and other affective disorders, such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder responsive to serotonin reuptake inhibitor.
PCT/DK2004/000862 2003-12-15 2004-12-14 The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist WO2005056056A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2006543369A JP2007513896A (en) 2003-12-15 2004-12-14 Combination of serotonin reuptake inhibitor and histamine 3 receptor antagonist, inverse agonist or partial agonist
US10/596,348 US20070066601A1 (en) 2003-12-15 2004-12-14 Combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
CA002549574A CA2549574A1 (en) 2003-12-15 2004-12-14 The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
EA200601158A EA200601158A1 (en) 2003-12-15 2004-12-14 COMBINATION OF SEROTONIN RETURN CAPTURE INHIBITOR AND ANTAGONIST, REVERSE AGONIST OR PARTIAL AGONIST OF HISTAMINE 3 RECEPTOR
EP04803015A EP1696896A2 (en) 2003-12-15 2004-12-14 The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
BRPI0415899-7A BRPI0415899A (en) 2003-12-15 2004-12-14 uses of a compound, and an h3 receptor antagonist, inverse agonist or partial agonist, pharmaceutical composition, method for identifying compounds useful for treating disease, and compound
AU2004296531A AU2004296531A1 (en) 2003-12-15 2004-12-14 The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
IS8388A IS8388A (en) 2003-12-15 2006-03-30 The mixture of serotonin reuptake inhibitors and histamine 3 receptor antagonists, potent or functional pain
IL176238A IL176238A0 (en) 2003-12-15 2006-06-11 The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
NO20063267A NO20063267L (en) 2003-12-15 2006-07-13 The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US52949103P 2003-12-15 2003-12-15
US60/529,491 2003-12-15
DKDKPA200301854 2003-12-15
DKPA200301854 2003-12-15

Publications (2)

Publication Number Publication Date
WO2005056056A2 WO2005056056A2 (en) 2005-06-23
WO2005056056A3 true WO2005056056A3 (en) 2006-02-02

Family

ID=34680191

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2004/000862 WO2005056056A2 (en) 2003-12-15 2004-12-14 The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist

Country Status (6)

Country Link
EP (1) EP1696896A2 (en)
JP (1) JP2007513896A (en)
AU (1) AU2004296531A1 (en)
BR (1) BRPI0415899A (en)
NO (1) NO20063267L (en)
WO (1) WO2005056056A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004019118D1 (en) 2003-09-17 2009-03-05 Janssen Pharmaceutica Nv CONDENSED HETEROCYCLIC COMPOUNDS AS MODULATORS OF THE SEROTONIN RECEPTOR
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
CA2691782A1 (en) 2007-09-11 2009-03-19 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole n-oxides
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020279A1 (en) * 1997-10-17 1999-04-29 Eli Lilly And Company Potentiation of pharmaceuticals
WO1999061027A1 (en) * 1998-05-22 1999-12-02 Eli Lilly And Company Combination therapy for treatment of refractory depression
EP0966967A2 (en) * 1998-05-29 1999-12-29 Eli Lilly And Company Combination therapy of olanzapine (zyprexa) and fluoxetine (prozac) for treatment of bipolar disorder
EP0978512A1 (en) * 1998-07-29 2000-02-09 Societe Civile Bioprojet Non-imidazole aryloxy (or arylthio) alkylamines as histamine H3-receptor antagonists and their therapeutic applications

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020279A1 (en) * 1997-10-17 1999-04-29 Eli Lilly And Company Potentiation of pharmaceuticals
WO1999061027A1 (en) * 1998-05-22 1999-12-02 Eli Lilly And Company Combination therapy for treatment of refractory depression
EP0966967A2 (en) * 1998-05-29 1999-12-29 Eli Lilly And Company Combination therapy of olanzapine (zyprexa) and fluoxetine (prozac) for treatment of bipolar disorder
EP0978512A1 (en) * 1998-07-29 2000-02-09 Societe Civile Bioprojet Non-imidazole aryloxy (or arylthio) alkylamines as histamine H3-receptor antagonists and their therapeutic applications

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BONGERS GERALD ET AL: "Role of H3-receptor-mediated signaling in anxiety and cognition in wild-type and Apoe-/- mice.", NEUROPSYCHOPHARMACOLOGY, vol. 29, no. 3, March 2004 (2004-03-01), pages 441 - 449, XP008056995, ISSN: 0893-133X *
MORISSET S ET AL: "Atypical neuroleptics enhance histamine turnover in brain via 5-hydroxytryptamine2A receptor blockade", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 288, no. 2, February 1999 (1999-02-01), pages 590 - 596, XP008056904, ISSN: 0022-3565 *
SCHLICKER E ET AL: "Effects of imidazolines on noradrenaline release in brain: An investigation into their relationship to imidazoline, [alpha]2 and H3 receptors", NEUROCHEMISTRY INTERNATIONAL 1997 UNITED KINGDOM, vol. 30, no. 1, 1997, pages 73 - 83, XP008056901, ISSN: 0197-0186 *

Also Published As

Publication number Publication date
AU2004296531A1 (en) 2005-06-23
JP2007513896A (en) 2007-05-31
WO2005056056A2 (en) 2005-06-23
EP1696896A2 (en) 2006-09-06
NO20063267L (en) 2006-07-13
BRPI0415899A (en) 2007-01-09

Similar Documents

Publication Publication Date Title
EP1749818A3 (en) Phenyl-piperazine derivatives as serotonin reuptake inhibitors
UA82828C2 (en) The use of enantiomeric pure escitalopram for treatment of depression
HRP20080478T3 (en) 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
WO2004047830A3 (en) Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor and the use of said composition for treating bladder dysfunction
CA2490638A1 (en) Combination therapy wherein a serotonin reuptake inhibitor is used
JP2006514952A5 (en)
NO20063267L (en) The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
WO2009109493A3 (en) 2-aminoquinoline derivatives as 5-ht ( 5a) receptor antagonists
NO20061167L (en) The combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression
DK1381613T3 (en) Antidepressant azaheterocyclyl methyl derivatives of oxaheterocyclo condensed 1,4-benzodioxanes
AU2002256334A1 (en) Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino(2,3-f)quinoxaline
NO20035673L (en) New heteroaryl derivatives, their preparation and use
EA200601158A1 (en) COMBINATION OF SEROTONIN RETURN CAPTURE INHIBITOR AND ANTAGONIST, REVERSE AGONIST OR PARTIAL AGONIST OF HISTAMINE 3 RECEPTOR
DK1401839T5 (en) Antidepressant (SSSRI) azaheterocyclyl methyl derivatives of 7,8-dihydro-3H-6,9-dioxa-1,3-diazacyclopenta [a] naphthalene
WO2007048080A3 (en) Stable pharmaceutical formulations containing escitalopram and bupropion
ATE323094T1 (en) ANTIDEPRESSANT CYCLOALKYLAMINE DERIVATIVES OF BENZODIOXANS CONDENSED WITH HETEROCYCLES
BRPI0412268A (en) compounds containing a selective serotonin reuptake inhibitor and 5-ht2a receptor antagonist
JP2007513896A5 (en)
AR039723A1 (en) COMBINATION THERAPY WHERE A SEROTONINE RECOVERY INHIBITOR IS USED
NO20060229L (en) Gaboxadol for the treatment of depression and other affective disorders
AR045284A1 (en) USE OF AN INHIBITOR COMPOUND FOR SEROTONINE RECOVERY AND AN INHIBITOR COMPOUND OF THE TYPE I GLICINE CARRIER FOR DEPRESSION TREATMENT
UA81472C2 (en) 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
CA2521030A1 (en) 4-(2-phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480037386.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 546181

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 12006500658

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2006/03397

Country of ref document: ZA

Ref document number: 200603397

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/005127

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 06046085

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2006543369

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004296531

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 176238

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2549574

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020067011860

Country of ref document: KR

Ref document number: 2107/CHENP/2006

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2004803015

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004296531

Country of ref document: AU

Date of ref document: 20041214

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004296531

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006124539

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 2007066601

Country of ref document: US

Ref document number: 1200601158

Country of ref document: VN

Ref document number: 10596348

Country of ref document: US

Ref document number: 200601158

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2004803015

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067011860

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0415899

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10596348

Country of ref document: US